MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
Vivos Therapeutics Operating Income 2011-2026 | VVOS
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Vivos Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.2 M | -17.3 M | -25 M | -20.4 M | -12 M | -10.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.6 M | -25 M | -16.1 M |
Quarterly Operating Income Vivos Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.73 M | -4.86 M | -3.92 M | - | -2.64 M | -1.94 M | -3.78 M | - | -3.64 M | -4.52 M | -5 M | - | -5.41 M | -6.96 M | -6.82 M | - | -5.5 M | -4.06 M | -3.41 M | - | -1.82 M | -1.42 M | -2.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.42 M | -6.96 M | -4.06 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Viemed Healthcare
VMD
|
22.9 M | $ 9.21 | -0.11 % | $ 358 M |  USA |
 |
Varex Imaging Corporation
VREX
|
-27.8 M | $ 10.82 | 0.37 % | $ 448 M | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Abbott Laboratories
ABT
|
8.05 B | $ 105.12 | 0.53 % | $ 183 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Align Technology
ALGN
|
608 M | $ 165.94 | -6.42 % | $ 12.4 B | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Beyond Air
XAIR
|
-44.5 M | $ 0.68 | -1.74 % | $ 46 M | USA |
 |
Accuray Incorporated
ARAY
|
7.84 M | $ 0.39 | 4.43 % | $ 40.1 M | USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 11.05 | -4.12 % | $ 1.66 B | USA |
 |
Xtant Medical Holdings
XTNT
|
-12.1 M | $ 0.57 | 0.5 % | $ 76.2 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
1.29 B | $ 88.45 | -0.79 % | $ 18 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 34.22 | -3.17 % | $ 5.1 K | USA |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 69.21 | -1.37 % | $ 102 B | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 35.63 | -2.76 % | $ 1.11 B | USA |
 |
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Cytosorbents Corporation
CTSO
|
-16.8 M | $ 0.59 | -1.68 % | $ 32.1 M | USA |
 |
Aethlon Medical
AEMD
|
-9.34 M | $ 2.22 | -2.2 % | $ 3.47 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 79.12 | -3.63 % | $ 46.3 B | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 11.15 | -2.28 % | $ 1.51 B | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 0.97 | -28.14 % | $ 15.6 M | USA |
 |
Penumbra
PEN
|
189 M | $ 335.13 | -0.38 % | $ 13 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 15.76 | -3.64 % | $ 370 M | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 61.5 | -3.38 % | $ 3.35 B |  Britain |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Ra Medical Systems
RMED
|
-27 M | - | 10.0 % | $ 610 K | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.68 | 0.43 % | $ 28.5 M | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 49.39 | -2.1 % | $ 1.45 B | USA |
 |
Pulmonx Corporation
LUNG
|
-53.7 M | $ 1.17 | -5.65 % | $ 47.6 M | USA |